 |
XOMA Acquires U.S. Rights to Perindopril Franchise and Establishes Commercial Operations
Jan 17, 2012
|
17.7 KB |
|
| |
BERKELEY, Calif., Jan. 17, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) today announced it has acquired U.S. rights to the perindopril franchise from Les Laboratoires Servier, XOMA's partner for its lead product candidate, gevokizumab (formerly XOMA 052). The agreement includes the branded product ACEON® (perindopril erbumine), a cu...
|
|
XOMA Streamlines Operations to Invest in Value-Creating Activities
Jan 5, 2012
|
17.9 KB |
|
| |
BERKELEY, Calif., Jan. 5, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) today announced it has implemented significant organizational and structural changes that are designed to sharpen the Company's focus on value-creating opportunities led by gevokizumab (XOMA 052) and the Company's unique antibody discovery and development capabilities...
|
|
Photo Release -- XOMA Appoints John Varian as Chief Executive Officer
Jan 5, 2012
|
49.8 KB |
|
| |
BERKELEY, Calif., Jan. 5, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) today announced its Board of Directors has appointed John Varian as Chief Executive Officer. Mr. Varian has been serving as the Interim Chief Executive since August 31, 2011, and has been a member of the Board since December 2008. The Board's decision followed a full ...
|
|
XOMA Secures $10 Million Term Loan
Jan 3, 2012
|
14.4 KB |
|
| |
BERKELEY, Calif., Jan. 3, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that it has entered into a $10.0 million 42-month secured term loan agreement with GE Capital, Healthcare Financial Services. The funds will be used for advancement of gevokizumab (XOMA 052...
|
|
XOMA Will Move Its Corporate Domicile to Delaware
Dec 30, 2011
|
12.2 KB |
|
| |
BERKELEY, Calif., Dec. 30, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced that, effective December 31, 2011, it will move its corporate domicile from Bermuda to Delaware and change its name from "XOMA Ltd." to "XOMA Corporation."
All of the outstanding common shares of the former XOMA Ltd. will automatically convert by ope...
|
|
XOMA Initiates Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris
Dec 21, 2011
|
16.7 KB |
|
| |
BERKELEY, Calif., Dec. 21, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced it has begun dosing patients in its Phase 2 proof-of-concept study to evaluate the efficacy and safety of gevokizumab (XOMA 052), a potent inhibitor of interleukin-1 beta (IL-1 beta), for the treatment of the inflammatory lesions seen in moderate to severe a...
|
|
XOMA Announces Presentation and Webcast at Lazard Capital Markets Healthcare Conference
Nov 10, 2011
|
15.1 KB |
|
| |
BERKELEY, Calif., Nov. 10, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that John Varian, Interim Chief Executive Officer, and Paul Rubin, M.D., Vice President, Clinical Development and Chief Medical Officer, will present on behalf of the Company at the Eighth Annual...
|
|
XOMA Reports Third Quarter 2011 Financial Results
Nov 9, 2011
|
24.6 KB |
|
| |
BERKELEY, Calif., Nov. 9, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the third quarter ended September 30, 2011. XOMA had total revenues of $16.2 million in the third quarter of 2011, compared with $10.9 million in the third quarter...
|
|
XOMA Expands Gevokizumab (XOMA 052) Program
Nov 9, 2011
|
22.3 KB |
|
| |
BERKELEY, Calif., Nov. 9, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced the expansion of its gevokizumab (XOMA 052) program. XOMA and its partner, Les Laboratoires Servier, are in the process of implementing a broader Phase 3 program to include the patient popu...
|
|
XOMA to Announce Third Quarter 2011 Financial Results and Host Webcast Conference Call on November 9
Nov 3, 2011
|
15.7 KB |
|
| |
BERKELEY, Calif., Nov. 3, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that the company will host a webcast conference call on Wednesday, November 9, 2011 at 4:30 p.m. Eastern time to discuss third quarter 2011 financial results and provide a general business update....
|
|
XOMA Announces Presentation and Webcast at BIO Investor Forum
Oct 18, 2011
|
15.4 KB |
|
| |
BERKELEY, Calif., Oct. 18, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that Fred Kurland, Vice President and Chief Financial Officer, will present a business overview at the Tenth Annual BIO Investor Forum in San Francisco on Tuesday, October 25, 2011 at 8:30 a.m. P...
|
|
XOMA and Aragen Bioscience Announce Antibody Humanization Services Agreement
Oct 18, 2011
|
8.9 KB |
|
| |
Berkeley and Morgan Hill, CA, October 18, 2011 -- XOMA Ltd. (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, and Aragen Bioscience, Inc., a provider of high-content preclinical research and development services, have entered into an agreement under which Aragen Bioscience will provide its clients access to X...
|
|
XOMA Announces Proposed Domestication to Delaware
Oct 4, 2011
|
12.7 KB |
|
| |
BERKELEY, Calif., Oct. 4, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) today announced its intention to change its jurisdiction of incorporation from Bermuda to Delaware (the "Domestication"). The Company's Board of Directors believes that this change will:
provide legal, administrative and other similar efficiencies, as well as p...
|
|
XOMA Presents Data on Novel Antitoxins in Development for Botulism Poisoning
Oct 3, 2011
|
16.8 KB |
|
| |
BERKELEY, Calif., Oct. 3, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced several presentations highlighting its expertise in the development of recombinant antitoxins for botulism poisoning. The presentations will be made at the Seventh Triennial Basic and Therapeutic...
|
|
XOMA Secures Federal Contract to Expand Its Next-Generation Human Botulism Antitoxin Portfolio
Oct 3, 2011
|
16.1 KB |
|
| |
BERKELEY, Calif., Oct. 3, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, has been awarded a new contract for up to $28 million over five years to develop broad-spectrum antitoxins for the treatment of human botulism poisoning. The botulinum toxin, which causes botulism poisonin...
|
|
XOMA Announces Management Changes
Aug 31, 2011
|
17.5 KB |
|
| |
BERKELEY, Calif., Aug. 31, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) announced today Steve Engle has chosen to resign from his positions as Chief Executive Officer, President and Chairman of the Board, effective August 31, 2011. As a result, the Board has appointed John Varian, a current Board member, as interim Chief Executive Officer and W...
|
|
XOMA Announces Presentation and Webcast at Wedbush Securities 2011 Life Sciences Conference
Aug 10, 2011
|
15.4 KB |
|
| |
BERKELEY, Calif., Aug. 10, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that company management will present a business overview at the Wedbush Securities Life Sciences Management Access Conference on Wednesday, August 17, 2011 at 8:00 a.m. Eastern time (5:00 a.m. Pa...
|
|
XOMA Reports Second Quarter 2011 Financial Results
Aug 4, 2011
|
26.4 KB |
|
| |
BERKELEY, Calif., Aug. 4, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the second quarter and six months ended June 30, 2011 and provided a general business update.
XOMA had total revenues of $16.5 million in the second quarte...
|
|
XOMA to Announce Second Quarter 2011 Financial Results and Host Webcast Conference Call on August 4
Jul 28, 2011
|
16.0 KB |
|
| |
BERKELEY, Calif., July 28, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that the company will host a webcast conference call on Thursday, August 4, 2011 at 4:30 p.m. Eastern time to discuss second quarter 2011 financial results and provide a general business update.
...
|
|
XOMA Discovers Two New Classes of Insulin Receptor-Regulating Antibodies
Jun 27, 2011
|
16.5 KB |
|
| |
SAN DIEGO, June 27, 2011 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq: XOMA), a leader in the discovery and development of therapeutic antibodies, announced the first presentation of results from its discovery of two new classes of fully human monoclonal antibodies that activate or sensitize the insulin receptor in vivo, each representing a distinct new t...
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz
